p11 and gene therapy for severe psychiatric disorders: A practical goal?

Science Translational Medicine

Volumn 2, Issue 54, 2010, Pages

  Chen, Guang ^a   Twyman, Roy ^a   Manji, Husseini K ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; IMIPRAMINE; MESSENGER RNA; MOOD STABILIZER; PARVOVIRUS VECTOR; PROTEIN P11; SEROTONIN UPTAKE INHIBITOR; UNCLASSIFIED DRUG; LIPOCORTIN 2; PROTEIN S 100; S100 CALCIUM BINDING PROTEIN A10;

BEHAVIOR DISORDER; BRAIN LEVEL; BRAIN REGION; DEPRESSION; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; ELECTROCONVULSIVE THERAPY; GENE SILENCING; GENE TRANSFER; HUMAN; NERVE CELL PLASTICITY; NONHUMAN; NUCLEUS ACCUMBENS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; ADENO ASSOCIATED VIRUS; ANIMAL; GENE THERAPY; GENE VECTOR; GENETICS; MOUSE; NOTE;

ANIMALS; ANNEXIN A2; DEPENDOVIRUS; DEPRESSION; GENE THERAPY; GENETIC VECTORS; HUMANS; MICE; S100 PROTEINS;

EID: 77958575621     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3001754     Document Type: Review

References (36)

1. R. S. Duman, Neuronal damage and protection in the pathophysiology and treatment of psychiatric illness: Stress and depression. Dialogues Clin. Neurosci. 11, 239-255 (2009).
2. V. Krishnan, E. J. Nestler, The molecular neurobiology of depression. Nature 455, 894-902 (2008).
3. H. K. Manji, W. C. Drevets, D. S. Charney, The cellular neurobiology of depression. Nat. Med. 7, 541-547 (2001).
4. G. Chen, I. D. Henter, H. K. Manji, Translational research in bipolar disorder: Emerging insights from genetically based models. Mol. Psychiatry 15, 883-895 (2010).
5. B. Alexander, J. Warner-Schmidt, T. Eriksson, C. Tamminga, M. Arango-Llievano, S. Ghose, M. Vernov, M. Stavarche, S. Musatov, M. Flajolet, P. Svenningsson, P. Greengard, M. G. Kaplitt, Reversal of depressed behaviors in mice by p11 gene therapy in the nucleus accumbens. Sci. Transl. Med., 2, 54ra76 (2010).
6. T. R. Insel, P. S. Wang, The STAR*D trial: Revealing the need for better treatments. Psychiatr. Serv. 60, 1466-1467 (2009).
7. S. Zisook, K. Ganadjian, C. Moutier, R. Prather, S. Rao, Sequenced Treatment Alternatives to Relieve Depression, (STAR*D): Lessons learned. J. Clin. Psychiatry 69, 1184-1185 (2008).
8. The National Advisory Mental Health Council's Workgroup (2010), www.mentalhealth.gov/about/advisory-boards-and-groups/namhc/namhc-workgroups/ index.shtml.
9. E. J. Nestler, E. Gould, H. Manji, M. Buncan, R. S. Duman, H. K. Greshenfeld, R. Hen, S. Koester, I. Lederhendler, M. Meaney, T. Robbins, L. Winsky, S. Zalcman, Preclinical models: Status of basic research in depression. Biol. Psychiatry 52, 503-528 (2002).
10. N. Li, B. Lee, R. J. Liu, M. Banasr, J. M. Dwyer, M. Iwata, X. Y. Li, G. Aghajanian, R. S. Duman, mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 329, 959-964 (2010).
11. G. Sanacora, C. A. Zarate, J. H. Krystal, H. K. Manji, Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat. Rev. Drug Discov. 7, 426-437 (2008).
12. P. Svenningsson, K. Chergui, I. Rachleff, M. Flajolet, X. Zhang, M. El Yacoubi, J. M. Vaugeois, G. G. Nomikos, P. Greengard, Alterations in 5-HT1B receptor function by p11 in depression-like states. Science 311, 77-80 (2006).
13. S. Szabo, T. D. Gould, H. K. Manji, Neurotransmitters, receptors, signal transduction pathways and second messengers, in American Psychiatric Textbook of Psychopharmacology, C. B. Nemeroff, A. F. Schatzberg, Eds. (American Psychiatric Press, Washington DC, 2009), pp. 3-52.
14. P. Svenningsson, P. Greengard, p11 (S100A10) - An inducible adaptor protein that modulates neuronal functions. Curr. Opin. Pharmacol. 7, 27-32 (2007).
15. J. L. Warner-Schmidt, M. Flajolet, A. Maller, E. Y. Chen, H. Qi, P. Svenningsson, P. Greengard, Role of p11 in cellular and behavioral effects of 5-HT4 receptor stimulation. J. Neurosci. 29, 1937-1946 (2009).
16. H. Anisman, L. Du, M. Palkovits, G. Faludi, G. G. Kovacs, P. Szontagh-Kishazi, Z. Merali, M. O. Poulter, Serotonin receptor subtype and p11 mRNA expression in stress-relevant brain regions of suicide and control subjects. J. Psychiatry Neurosci. 33, 131-141 (2008).
17. J. Hunsberger, D. R. Austin, I. D. Henter, G. Chen, The neurotrophic and neuroprotective effects of psychotropic agents. Dialogues Clin. Neurosci. 11, 333-348 (2009).
18. B. A. Hoshaw, J. E. Malberg, I. Lucki, Central administration of IGF-I and BDNF leads to long-lasting antidepressant-like effects. Brain Res. 1037, 204-208 (2005).
19. J. A. Siuciak, D. R. Lewis, S. J. Wiegand, R. M. Lindsay, Antidepressant-like effect of brain-derived neurotrophic factor (BDNF). Pharmacol. Biochem. Behav. 56, 131-137 (1997).
20. Y. Shirayama, A. C. Chen, S. Nakagawa, D. S. Russell, R. S. Duman, Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression. J. Neurosci. 22, 3251-3261 (2002).
21. J. L. Warner-Schmidt, E. Y. Chen, X. Zhang, J. J. Marshall, A. Morozov, P. Svenningsson, P. Greengard, A role for p11 in the antidepressant action of brain-derived neurotrophic factor. Biol. Psychiatry 68, 528-535 (2010).
22. J. Kim, K. A. Hajjar, Annexin II: A plasminogen-plasminogen activator co-receptor. Front. Biosci. 7, d341-d348 (2002).
23. K. Martinowich, H. K. Manji, B. Lu, New insights into BDNF function in depression and anxiety. Nat. Neurosci. 10, 1089-1093 (2007).
24. E. J. Nestler, S. E. Hyman, Animal models of neuropsychiatric disorders. Nat. Neurosci. 13, 1161-1169 (2010).
25. R. F. Tzang, C. J. Hong, Y. J. Liou, Y. W. Yu, T. J. Chen, S. J. Tsai, Association study of p11 gene with major depressive disorder, suicidal behaviors and treatment response. Neurosci. Lett. 447, 92-95 (2008).
26. R. Verma, D. J. Cutler, P. Holmans, J. A. Knowles, R. R. Crowe, W. A. Scheftner, M. M. Weissman, J. R. DePaulo Jr., D. F. Levinson, J. B. Potash, Investigating the role of p11 (S100A10) sequence variation in susceptibility to major depression. Am. J. Med. Genet. B. Neuropsychiatr. Genet. 144B, 1079-1082 (2007).
27. L. Zhang, H. Li, T. P. Su, J. L. Barker, D. Maric, C. S. Fullerton, M. J. Webster, C. J. Hough, X. X. Li, R. Ursano, Traumatic Stress Brain Study Group, p11 is up-regulated in the forebrain of stressed rats by glucocorticoid acting via two specific glucocorticoid response elements in the p11 promoter. Neuroscience 153, 1126-1134 (2008).
28. E. J. Nestler, W. A. Carlezon Jr., The mesolimbic dopamine reward circuit in depression. Biol. Psychiatry 59, 1151-1159 (2006).
29. T. A. Green, I. N. Alibhai, S. Unterberg, R. L. Neve, S. Ghose, C. A. Tamminga, E. J. Nestler, Induction of activating transcription factors (ATFs) ATF2, ATF3, and ATF4 in the nucleus accumbens and their regulation of emotional behavior. J. Neurosci. 28, 2025-2032 (2008).
30. A. J. Eisch, C. A. Bolaños, J. de Wit, R. D. Simonak, C. M. Pudiak, M. Barrot, J. Verhaagen, E. J. Nestler, Brain-derived neurotrophic factor in the ventral midbrain-nucleus accumbens pathway: A role in depression. Biol. Psychiatry 54, 994-1005 (2003).
31. T. E. Schlaepfer, M. X. Cohen, C. Frick, M. Kosel, D. Brodesser, N. Axmacher, A. Y. Joe, M. Kreft, D. Lenartz, V. Sturm, Deep brain stimulation to reward circuitry alleviates anhedonia in refractory major depression. Neuropsychopharmacology 33, 368-377 (2008).
32. B. H. Bewernick, R. Hurlemann, A. Matusch, S. Kayser, C. Grubert, B. Hadrysiewicz, N. Axmacher, M. Lemke, D. Cooper-Mahkorn, M. X. Cohen, H. Brockmann, D. Lenartz, V. Sturm, T. E. Schlaepfer, Nucleus accumbens deep brain stimulation decreases ratings of depression and anxiety in treatment-resistant depression. Biol. Psychiatry 67, 110-116 (2010).
33. M. G. Kaplitt, A. Feigin, C. Tang, H. L. Fitzsimons, P. Mattis, P. A. Lawlor, R. J. Bland, D. Young, K. Strybing, D. Eidelberg, M. J. During, Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: An open label, phase I trial. Lancet 369, 2097-2105 (2007).
34. S. Worgall, D. Sondhi, N. R. Hackett, B. Kosofsky, M. V. Kekatpure, N. Neyzi, J. P. Dyke, D. Ballon, L. Heier, B. M. Greenwald, P. Christos, M. Mazumdar, M. M. Souweidane, M. G. Kaplitt, R. G. Crystal, Treatment of late infantile neuronal ceroid lipofuscinosis by CNS administration of a serotype 2 adeno-associated virus expressing CLN2 cDNA. Hum. Gene Ther. 19, 463-474 (2008).
35. The World Health Organization, World Health Report 2001 (WHO, Geneva, 2000).
36. Competing interests: The authors declare that they have no competing interests.